51 results about "Roseburia" patented technology

The present invention relates to Roseburia flagellin, and / or a polynucleotide sequence encoding said Roseburia flagellin, and / or a vector comprising said polynucleotide sequence, and / or a host cell, including bacteria, comprising said vector, and / or a host cell, including bacteria, comprising said polynucleotide sequence, for use in modulating the inflammation of a tissue or an organ in a subject.

The present invention relates to Roseburia flagellin, and / or a polynucleotide sequence encoding said Roseburia flagellin, and / or a vector comprising said polynucleotide sequence, and / or a host cell, including bacteria, comprising said vector, and / or a host cell, including bacteria, comprising said polynucleotide sequence, for use in modulating the inflammation of a tissue or an organ in a subject.

A method for reducing the likelihood of developing non-alcoholic steatohepatitis (NASH) in an individual diagnosed with non-alcoholic fatty liver disease involves providing in the gut of an individual a population of beneficial bacteria selected from the group consisting of Lactobacillus species, and at least 6 grams per day of fiber to the individual to maintain a therapeutically effective amount of the beneficial bacteria in the gut of the individual. In certain embodiments, monoacylglycerolacyltransferase-3 (MGAT3) synthesis is inhibited to lower triacylglycerol (TAG) production, while in others, expression of diacylglycerolacyltransferase-2 (DGAT-2) is inhibited. The beneficial bacteria are preferably modified to produce increased amounts of butyrate and are also encapsulated in a frangible enclosure. Levels of Roseburia are preferably increased while the levels of Akkermansia spp. in the individual's gut microbiome are reduced.

The present invention relates to a biomarker for risk prediction or diagnosis of metabolic and inflammatory diseases, and use thereof. The biomarker is formulated to detect a group of microorganisms consisting of Akkermansia muciniphila, Bacteroides spp., Eubacterium spp., Roseburia spp., Methanobrevibacter smithii, Methanosphaera stadtmanae, Ruminococcus obeum, and Phascolarctobacterium.

A method for reducing the likelihood of developing non-alcoholic steatohepatitis (NASH) in an individual diagnosed with non-alcoholic fatty liver disease involves providing in the gut of an individual a population of beneficial bacteria selected from the group consisting of Lactobacillus species, and at least 6 grams per day of fiber to the individual to maintain a therapeutically effective amount of the beneficial bacteria in the gut of the individual. In certain embodiments, monoacylglycerolacyltransferase-3 (MGAT3) synthesis is inhibited to lower triacylglycerol (TAG) production, while in others, expression of diacylglycerolacyltransferase-2 (DGAT-2) is inhibited. The beneficial bacteria are preferably modified to produce increased amounts of butyrate and are also encapsulated in a frangible enclosure. Levels of Roseburia are preferably increased while the levels of Akkermansia spp. in the individual's gut microbiome are reduced.

A method for treating an individual suffering from one of bladder cancer and colorectal cancer employs a CRISPR system to selectively kill or reduce the numbers of pathogenic bacteria within the individual and the individual is then administered an immune checkpoint inhibitor. In particular embodiments, the pathogenic bacteria is one of E. coli, Pseudomonas aeruginosa and Klebsiella bacteria, and the checkpoint inhibitor is selected from the group consisting of nivolumab, pembrolizumab, pidilizumab, AMP-224, AMP-514, STI-A1110, TSR-042, RG-7446, BMS-936559, MEDI-4736, MSB-0020718C, AUR-012 and STI-A1010. Further embodiments include enhancing the growth of a second bacteria in the individual, such bacteria including Akkermansia, Bacteroides, Bifidobacterium, Clostridium, Enterococcus, Fusobacterium, Lactobacillus, Propionibacterium, Ruminococcus, Veillonella, Prevotella, Escherichia and Streptococcus. Still other embodiments include increasing the levels of Roseburia and / or Faecalibacterium prausnitzii, in the individual's gut microbiome.

The invention relates to the fields of genetic engineering and biomedicine, and more specifically relates to a biomarker of schizophrenia and its application. The invention discloses a marker of schizophrenia and its application in preparing a kit for diagnosing schizophrenia, and also discloses a kit for detecting the marker. The schizophrenia markers disclosed in the present invention include Prevotella, Succinivibrio, Fusobacterium, Lactobacillus, and Megasphaera , Acidaminococcus, Citrobacter, Phascolarctobacterium, Coprococcus, Roseburia, Blautia 11 species At least 5 of the microorganisms. The marker provided by the invention can judge schizophrenia and normal people, the AUC is above 0.81, has good diagnostic efficiency, and can be used to prepare a kit for effectively diagnosing schizophrenia.

The invention provides application of Roseburia to treatment and prevention of obesity related disease. The invention provides the application of Roseburia to the treatment and prevention of obesity related diseases, and a composition for treatment and prevention of obesity related diseases, wherein the composition comprises drug, drink, food, or animal feed composition; besides, a method for reducing the weight and / or blood sugar is also provided.

The invention discloses a purpose of Moringaceae powder for regulating animal intestinal flora, and food and medicine containing Moringaceae powder. The Moringaceae powder can significantly increase the number of such probiotics in animal intestines as lactobacillus acetotoleran, butyrivibrio, Luosibairui Escherichia, Roseburia Stanton and Savage and the like and significantly regulate the animal intestinal flora, so as to achieve an effect for preventing and treating diabetes, hypertension and hyperlipidemia through the functions of the intestinal flora.

A method for reducing the likelihood of developing liver cancer in an individual diagnosed with non-alcoholic fatty liver disease involves providing in the gut of an individual a population of beneficial bacteria selected from the group consisting of Lactobacillus species, and administering fiber to the individual to maintain a therapeutically effective amount of the beneficial bacteria in the gut of the individual. In certain embodiments, monoacylglycerolacyltransferase-3 (MGAT3) synthesis is inhibited to lower triacylglycerol (TAG) production, while in others, expression of diacylglycerolacyltransferase-2 (DGAT-2) is inhibited. The beneficial bacteria are preferably modified to produce increased amounts of butyrate and may also be encapsulated in a frangible enclosure. Levels of Roseburia are preferably increased while the levels of Akkermansia spp. in the individual's gut microbiome are reduced. In other embodiments, a therapeutically effective amount of a bacterial formulation comprising Faecalibacterium prausnitzii is administered, or a composition comprising modified L. reuteri bacteria having the ability to survive conditions in the duodenum or jejunum of the individual's small intestine. Other embodiments include the administration of a bacterial formulation comprising at least one of Coprococcus, Veillonella, Roseburia, Bifidobacterium, Faecalibacterium prausnitzii and Prevotella.

The invention discloses application of Fuzhuan tea in regulation of animal intestinal flora. The Fuzhuan tea can be used for obviously increasing the number of such probiotics in animal intestines as lactobacillus acetotoleran, butyrivibrio, Luosibairui Escherichia, Roseburia Stanton and Savage and the like and significantly regulating the animal intestinal flora, so as to achieve an effect of reducing blood fat through the functions of the intestinal flora.

The invention relates to the field of clinical microorganism detection, and provides a kit and a method for rapidly detecting and identifying mycobacteria in a clinical sample. The kit comprises two universal primers used for amplifying mycobacterium 16S rRNA variable region sequences, a specific primer used for shielding Rogowski bacterium 16S rRNA variable region, a specific primer used for shielding corynebacterium bacterium 16SrRNA variable region, a sequencing primer used for determining the sequence of a forward segment of amplified mycobacterium specific fragment, and avidin-labeled magnetic beads. A sequencing result is compared with a database to judge species. The kit can be used for detecting and identifying mycobacteria in clinical samples, and can be used for clinical diagnosis of suspected mycobacteria infection in various clinical samples. The kit not only wins precious rescue time for clinical diagnosis and treatment, but also has the advantages of being low in cost, convenient to operate and high in specificity.

A person's intestinal (gut), oral or skin microbiota is modified using specific combinations of pre-biotics, pro-biotics and / or anti-biotics to establish a defined microbiota that can treat and / or reduce the likelihood that individuals will experience various diseases, including cancer. The employment of various bacteria, whether in particular combinations or after being modified using CRISPR-type systems, leads to improved outcomes when checkpoint inhibitors are used to treat various forms of cancer. One embodiment is directed to a method for reducing the likelihood of developing cancer by providing in the gut of an individual a population of beneficial bacteria selected from the group consisting of Lactobacillus species. The level of Roseburia and Faecalibacterium prausnitzii, and / or Akkermansia muciniphila bacteria are increased in the individual's gut microbiome such that when an individual is administered an immune checkpoint inhibitor, its function is enhanced due to the presence of the bacterial population.

A person's intestinal (gut), oral or skin microbiota is modified using specific combinations of pre-biotics, pro-biotics and / or anti-biotics to establish a defined microbiota that can treat and / or reduce the likelihood that individuals will experience various diseases, including cancer. The employment of various bacteria, whether in particular combinations or after being modified using CRISPR-type systems, leads to improved outcomes when checkpoint inhibitors are used to treat various forms of cancer. One embodiment is directed to a method for reducing the likelihood of developing cancer by providing in the gut of an individual a population of beneficial bacteria selected from the group consisting of Lactobacillus species. The level of Roseburia and Faecalibacterium prausnitzii, and / or Akkermansia muciniphila bacteria are increased in the individual's gut microbiome such that when an individual is administered an immune checkpoint inhibitor, its function is enhanced due to the presence of the bacterial population.

The invention discloses application of N-acetylneuraminic acid in preparation of an accelerant for promoting Roseburia proliferation. An intervention experiment of the N-acetylneuraminic acid shows that the N-acetylneuraminic acid has the effects of regulating intestinal flora, particularly promoting Roseburia proliferation and increasing Roseburia abundance, so that the N-acetylneuraminic acid can be used as the proliferation accelerant; large-scale fermentation culture of Roseburia is carried out in vitro to prepare a corresponding probiotic agent, and the probiotic agent can also be used as a prebiotic drug, a functional food or a health food to act in vivo, so that intestinal flora disorder is effectively prevented and / or treated; and the N-acetylneuraminic acid can be used for treating various diseases related to Roseburia, including Crohn, gout, cirrhosis, constipation, depression and type 2 diabetes mellitus, namely, the new application of the N-acetylneuraminic acid is found for the first time, and the N-acetylneuraminic acid has extremely high application value in medical health care and industrial production.

A method for reducing the likelihood of developing depression in an individual involves providing in the gut of an individual a population of beneficial bacteria selected from the group consisting of bacterial species able to make small chain fatty acids, and preferably butyrate, and administering fiber to the individual to maintain a therapeutically effective amount of the beneficial bacteria in the gut of the individual. The individual's gut microbiome is modified to reduce the number of undesired bacteria and to increase the number of beneficial bacteria. Bacteria are preferably modified to remove one or more virulence facts or alternatively to produce increased amounts of SCFA's, such as butyrate. Beneficial bacteria may be encapsulated in a frangible enclosure to ensure they arrive in an individual's body while still viable, e.g. such as being first released in the lower gut rather than being exposed to the harsh conditions of an individual's stomach. In other embodiments, a therapeutically effective amount of a bacterial formulation comprising Faecalibacterium prausnitzii is administered. Other embodiments include the administration of a bacterial formulation comprising at least one of Coprococcus, Roseburia, Bifidobacterium, Faecalibacterium prausnitzii and L. casei to treat depression.

Provided herein are compositions comprising bacterial mixtures of strains from genera including Roseburia, Dorea, Bacteroides, Coprobacter, Agathobaculum, Lawsonibacter, Tyzzerella, Phascolarctobacterium, Enorma, Faecalimonas, lllomasclavelia, Clostridium, Fournierella, and / or Massilimicrobiota. Also provided are methods of using compositions comprising such bacterial mixtures. In some embodiments, it includes compositions, kits, and methods that are useful, e.g., for treatment and / or prevention of inflammatory bowel disease (IBD), such as ulcerative colitis (UC).

The present invention provides a prophylactic or therapeutic composition for graft-versus-host disease (GVHD). There is provided a prophylactic or therapeutic composition for GVHD, which comprises bacteria belonging to any genus selected from the group consisting of the following genera: Blautia, Clostridium, unclassified Clostridiales, Actinomyces, Parabacteroides, Lachnoclostridium, Bacteroides, Faecalibacterium, unclassified Lachnospiraceae, Roseburia, Ruminococcus, unclassified Firmicutes, Dorea, Phascolarctobacterium, Sutterella, Megamonas, Collinsella, Eubacterium, and Coprococcus, etc., or any combination of bacteria belonging to these genera.

The invention relates to the technical field of biological materials, in particular to 4-hydroxybutyrate coenzyme A transferase and application thereof. The 4-hydroxybutyrate coenzyme A transferase has an amino acid sequence as shown in SEQ ID NO: 1. According to the 4-hydroxybutyric acid coenzyme A transferase provided by the embodiment of the invention, the proportion of 4-hydroxybutyric acid or 3-hydroxyhexanoic acid in PHA synthesized by eutrophus Rosei and halomonas can be remarkably increased. The engineering modified bacterium containing the 4-hydroxybutyric acid coenzyme A transferase provided by the embodiment of the invention can realize the PHA content of 8.58 g / L, and the molar ratio of 4-hydroxybutyric acid is as high as 46.4%.

The present invention relates to the therapeutic intervention of chronic pain, in particular to the treatment of chronic pain using selected probiotic strains having analgesic properties, in particular three probiotics, Roseburia intestinae, Lacnospiraceae bacteria and Roseburia hominis, and a sterile secretion filtrate of Roseburia intestinae, which when administered in sufficient doses exhibit significant analgesic properties in the sciatic nerve branch selective injury (SNI) model.

The invention belongs to the field of life sciences, and in particular relates to the new application of Roseburia in preventing and treating anxiety and depression. The invention provides the application of Roseburia in preparing medicines for preventing and treating anxiety and depression. The consumption of described Roseburia (Roseburia) viable bacteria is every day 1 * 10 4 -1×10 20 CFU / mL.

The present invention provides a method, wherein the method treats a subject having a dysbiosis, the method comprising: determining a first metabolic profile of the gut microbiome of a subject having a dysbiosis; changing the first metabolic profile of the gut microbiome of the subject to a second metabolic profile of the gut microbiome of the subject, by administering to the subject a composition comprising at least one bacterial species selected from the group consisting of: Acidaminococcus intestinalis, Bacteriodes ovatus, Bifidobacterium adolescentis, Bifidobacterium longum, Blautia sp., Clostridium sp., Collinsella aerofaciens, Escherichia coli, Eubacterium desmolans, Eubacterium eligens, Eubacterium limosum, Faecallbacterum prausnitzii, Lachnospira pectinoshiza, Lactobacillus casei, Parabacteroides distasonis, Roseburia faecalis, Roseburia intestinalis, Ruminococcus sp., Ruminococcus species, and Ruminococcus torques, wherein the composition is administered at a therapeutically effective amount, sufficient to alter the first metabolic profile of the gut microbiome to the second metabolic profile of the gut microbiome.

The present invention is directed to beneficially directing the bidirectional communication that exists between the brain and the gut so as to influence brain physiology, psychological responses and ultimately behavior in a positive manner by regulating an individual's mood, psychological symptoms, such as anxiety and depression and stress-related changes in brain function, by modifying the gut microbiome of an individual. In various embodiments, an individual's microbiome is modified in a manner to reduce the likelihood of stress, to reduce or treat symptoms affecting mental health and to promote the mental health of the individual. In certain embodiments, administration to an individual of at least three different bacteria species are combined to modify an individual's microbiome, selected from the group of Lacticaseibacillus paracasei, Coprococcus, Roseburia, Bifidobacterium, L. casei and Faecalibacterium prausnitzii, to reduce adverse psychological and / or physiological responses attendant to psychological stress.

Present invention relates to the in vitro use of the level or concentration in a salivary or breath sample of bacteria belonging to the Alloprevotella, Prevotella, Campylobacter, Rothia, Catonella, Porphyromona, Fretibacterium genus, or any combination thereof, for the diagnosis of carcinomas or epidermoid cancers, especially epidermoid cancer of the head and neck, in a patient, or to obtain useful data that allow such a diagnosis.

The invention belongs to the technical field of medicines, and relates to application of intestinal Rosebariella in preparation of a tumor radiosensitizer. Research finds that the Roseburia intestinae can significantly improve the sensitivity of colorectal cancer to radiotherapy, which shows that after a colorectal cancer model mouse subjected to intragastric administration by the Roseburia intestinae is subjected to radiotherapy, the number of nodule is reduced, the size is reduced, the proliferation inhibition effect of colorectal cancer cells is improved, and the Roseburia intestinae can be used for preparing a colorectal cancer model mouse with the Roseburia intestinae. And the inflammation degree of the intestinal tract of the mouse subjected to local abdominal irradiation is reduced, so that the intestinal Rosiberia can be used as a tumor radiosensitizer, and the intestinal inflammation level is reduced.

The invention belongs to the technical field of biological medicines, and provides a Roseburia zhanii LC-95, which is preserved in the China General Microbiological Culture Collection Center on January 29, 2024, the China General Microbiological Culture Collection Center is called as CGMCC for short, the preservation number is CGMCC NO.29797, and the address of the preservation unit is No.3, Yard 1, Beichen West Road, Chaoyang District, Beijing. The strain has the effects of relieving constipation and cognitive impairment of middle-aged and elderly people, improving exercise coordination, relieving anxiety and the like.

The invention belongs to the technical field of medicines, and provides a preparation method of Rosella mucilaginosa vesicle composite gel aiming at the problem that application of bacterial membrane vesicles to treatment of actinic cheilitis is not researched yet at present, the preparation method comprises the following steps: S1, obtaining Rosella mucilaginosa; s2, preparation of Rosella mucilaginosa vesicles; and S3, preparation of the Rosella mucilaginosa vesicle composite gel. According to the invention, human symbiotic bacteria are used for culture and extraction, the active product has good biological safety and low sensitization, the vesicle treatment is easier to absorb, and the infection risk caused by direct use of viable bacteria is avoided; therefore, the Rosella mucilaginosa vesicle composite gel provided by the invention is beneficial to maintaining the health of the lips, resisting oxidative stress, reducing the generation of active oxygen, relieving porphyrin and iron overload of local tissues caused by ultraviolet rays, and improving the lip health. And a constructed rat actinic cheilitis model verifies that the Rosella mucilaginosa vesicle composite gel disclosed by the invention can be used for preventing and treating actinic cheilitis.

The present invention relates to an Alzheimer's disease marker and risk prediction model based on intestinal flora. The Alzheimer's disease marker based on intestinal flora includes intestinal flora, and the intestinal flora includes anaerobic Lawsonia sibiricum, Escherichia coli, Streptococcus salivarius, Asahidiella pseudomallei, Kluyveromyces pedis, intestinal Roseburia, Roseburia faecalis, Roseburia hominis, Firmicutes CAG424 bacteria and Clostridium CAG58 bacteria. The present invention mines Alzheimer's disease markers based on intestinal flora and further constructs an Alzheimer's disease risk prediction model based on intestinal flora, which has the characteristics of high detection accuracy, convenience, speed, safety and non-invasiveness, and has important clinical guidance significance for assisting the diagnosis of Alzheimer's disease-related indicators.